Feb 19 2021;doi:10.1093/ndt/gfab048 Tian S, Guo T, Qian F, et al
The research-grade material does not carry Health Canada authorization for any human or veterinary use, and Health Canada has stated in public advisories that unauthorized injectable peptide products are illegal regardless of 'research use only' labelling
et al: Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease
Design A narrative review by GHK's original researchers
Researchers are still working to understand the full range of semaglutides effects on the body, including its potential impact on nerve health
The STEP trials, which evaluated once-weekly semaglutide for chronic weight management, showed that patients on 2.4 mg experienced average weight loss of 15% body weight over 68 weeks compared to 2.6% for placebo